4.7 Article

Engineering bioactive nanoparticles to rejuvenate vascular progenitor cells

Journal

COMMUNICATIONS BIOLOGY
Volume 5, Issue 1, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s42003-022-03578-4

Keywords

-

Funding

  1. University of Notre Dame through Advancing Our Vision Initiative in Stem Cell Research
  2. Scientific Wellness Initiative, Harper Cancer Research Institute - American Cancer Society Institutional Research Grant [IRG-17-182-04]
  3. American Heart Association [19-CDA-34630012]
  4. National Institutes of Health [R01-HL-094725, R35-GM-143055]
  5. AngioBioCore at Indiana University Simon Comprehensive Cancer Center [NIDDK/NIH U54-DK-106846, P30 CA-082709]
  6. Indiana Clinical and Translational Science Institute (I-CTSI) - NIH [ULITR001108]

Ask authors/readers for more resources

This study presents a strategy to improve the vasculogenic potential of vascular progenitor cells exposed to gestational diabetes mellitus by conjugating drug-loaded liposomal nanoparticles to the surface of the cells. The strategy successfully rejuvenates the cells and improves their therapeutic potential, offering a promising approach to address cardiovascular complications and advance tissue repair and regenerative medicine.
Drug-loaded liposomal nanoparticles conjugated to endothelial colony-forming cells can improve the vasculogenic potential of vascular progenitor cells exposed to gestational diabetes mellitus. Fetal exposure to gestational diabetes mellitus (GDM) predisposes children to future health complications including type-2 diabetes mellitus, hypertension, and cardiovascular disease. A key mechanism by which these complications occur is through stress-induced dysfunction of endothelial progenitor cells (EPCs), including endothelial colony-forming cells (ECFCs). Although several approaches have been previously explored to restore endothelial function, their widespread adoption remains tampered by systemic side effects of adjuvant drugs and unintended immune response of gene therapies. Here, we report a strategy to rejuvenate circulating vascular progenitor cells by conjugation of drug-loaded liposomal nanoparticles directly to the surface of GDM-exposed ECFCs (GDM-ECFCs). Bioactive nanoparticles can be robustly conjugated to the surface of ECFCs without altering cell viability and key progenitor phenotypes. Moreover, controlled delivery of therapeutic drugs to GDM-ECFCs is able to normalize transgelin (TAGLN) expression and improve cell migration, which is a critical key step in establishing functional vascular networks. More importantly, sustained pseudo-autocrine stimulation with bioactive nanoparticles is able to improve in vitro and in vivo vasculogenesis of GDM-ECFCs. Collectively, these findings highlight a simple, yet promising strategy to rejuvenate GDM-ECFCs and improve their therapeutic potential. Promising results from this study warrant future investigations on the prospect of the proposed strategy to improve dysfunctional vascular progenitor cells in the context of other chronic diseases, which has broad implications for addressing various cardiovascular complications, as well as advancing tissue repair and regenerative medicine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available